CDH2 and melanoma: Targeting of NFATc2 by siRNA in three different melanoma cell lines (Fig. 2a), by shRNA in one cell line (Fig. 2b), and by treatment of three cell lines with AM404, an inhibitor that prevents NFATc2 binding to DNA [21] (Fig. 2c), led to strong downregulation of the EMT-markers ZEB1, N-cadherin, α-catulin and SNAIL, but upregulated E-cadherin, a marker of the mesenchymal to epithelial transition [22].